CLINICAL_TRIALS ClinicalTrials.gov record update

An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03525392
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:25.547272+00:00
Published At: 2023-12-12T00:00:00+00:00
Record Updated At: 2023-12-12
Results Posted At: 2023-12-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "Gastric Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Bone Cancer", "Advanced Cancer", "Recurrent Disease", "Metastatic Tumours"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-12"
protocolSection.identificationModule.nctId: "NCT03525392"
protocolSection.identificationModule.officialTitle: "An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-12-12"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.